Refine by
Drug Designation Suppliers & Manufacturers
81 companies found
based inMonterey, CALIFORNIA (USA)
Vybion has pioneered vectorized Intrabodies, the delivery of functional antibody fragments in the scFv format to cells using Adeno associated virus (AAV). The Company has Orphan Drug Designation from the FDA for INT41 to treat Huntington’s disease a ...
INT41 has received Orphan Drug Designation from the FDA for Huntington’s disease. IND enabling studies for INT41 Gene Therapy for Huntington’s disease are in place following a preIND meeting with the FDA ...
based inDaejeon, SOUTH KOREA
We are exploring sequence-based drug discovery and development, which is bypassing the need for 3D structure. ...
Dr. UG is an AI platform for developing new drugs that is based on DEARGEN’s deep learning technology. It specializes in genome data analysis, biomarker prediction, molecule selection and optimization. DEARGEN discovers new ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
Idiopathic pulmonary fibrosis [IPF] is a form of progressive pulmonary fibrosis, or abnormal scarring of the lungs. As the disease progresses, the increased scarring leads to decreasing transfer of oxygen into the bloodstream, and ultimately, ...
based inNangang Distric, TAIWAN
We are a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of best-in-class novel nanomedicines that combine our proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ...
By encapsulating molecules with poor solubility in polymeric micelle nanoparticles, TLC’s technology can increase the solubility of a drug. This allows a larger quantity to be delivered in a single dose, which can enable new ...
based inWayne, PENNSYLVANIA (USA)
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. Our ...
Approximately 12 subjects (N=3 per cohort) who have refractory angina will be enrolled into 4 ascending dose groups, followed by an expansion of the highest tolerated dose with 21 additional subjects. The trial is designed to test ...
based inMalvern, PENNSYLVANIA (USA)
We are a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. We leverage our expertise in superoxide dismutase ...
based inShirley, NEW YORK (USA)
After decades of research and accumulation, Creative Biolabs has become a leader in the discovery and manufacturing of recombinant antibodies (rAbs), providing the most reliable and qualified services to customers in academia and industry around the ...
The nucleic acid drug, as a novel therapeutic modality, can achieve long-lasting or even curative effects via gene regulations, replacement or editing. They have great potential to treat human diseases such as viral infections, cancers, and genetic ...
based in, NETHERLANDS
At veriNOS Pharmaceuticals, we focus on the clinical development of a drug that specifically inhibits a defined cascade that is relevant and common in different disease settings. The activation of iNOS with subsequent excessive production of cell ...
based in, MASSACHUSETTS (USA)
ProXyChem is a Massachusetts (USA) Limited Liability Company established in 2005 by Drs. Sherin S. Abdel-Meguid and Harold V. Meyers to provide cost effective, global drug discovery solutions to the pharmaceutical and biotechnology sectors. ...
ProXyChem’s management, collectively, has over 40 years of drug discovery experience. We provide consulting services in all aspects of the drug discovery ...
based inAustin, TEXAS (USA)
Headquartered in Austin, Texas, Lung Therapeutics, Inc. is a clinical stage biopharmaceutical company formed to leverage decades of leading research in orphan, pulmonary indications for which there are unmet medical needs. The company is developing ...
A pleural effusion is defined by the build-up of fluid in the pleural cavity, predominantly resulting from pneumonia. A loculated pleural effusion (LPE) occurs when scar tissue forms in the pleural cavity, trapping the fluid and preventing ...
based inPune, INDIA
ArrayGen Technologies Pvt Ltd is a Genomics service provider company with wide array of expertise in Genomics algorithm development, next generation sequencing(NGS), microarray, CADD and Bioinformatics services. Also, involved in various services in ...
based inSan Diego, CALIFORNIA (USA)
Capricor is Developing Transformative Cell and Exosome-based Therapeutics for the Treatment and Prevention of Diseases. Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a clinical-stage biotechnology company focused on the discovery, development, and ...
Our core therapeutic technology (CAP-1002) is based on cardiosphere-derived cells, or CDCs, a cardiac-derived cell therapy that was first identified in the academic laboratory of Capricor’s scientific founder, Dr. Eduardo Marbán. Since ...
based inSouth San Francisco, CALIFORNIA (USA)
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next-generation cancer therapeutics – antibody drug conjugates, bispecific ...
based inSan Francisco, CALIFORNIA (USA)
Atomwise is a technology-enabled pharmaceutical company leveraging the power of AI to revolutionize small molecule drug discovery. The Atomwise team invented the use of deep learning for structure-based drug design; this technology underpins ...
based inSan Francisco, CALIFORNIA (USA)
The invenious platform aims to enhance safety, efficacy, sterility, value and convenience. BioQ designs ready-to-use delivery systems for hard to prepare and hard to administer infusible drugs – thereby simplifying the infusion process from ...
based inCarlsbad, CALIFORNIA (USA)
Qualigen is a biotechnology company focused on the development of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its flagship FastPack diagnostic platform. The FastPack line of FDA-cleared and ...
Qualigen licensed the G4 selective transcription inhibitor platform from University College London (UCL) in 2022. The licensed technology comprises lead compound QN-302 (formerly SOP1812) and back-up compounds that target regulatory regions of ...
based inBaltimore, MARYLAND (USA)
SilcsBio provides software and services for unlocking the full potential of computer driven drug design. Our algorithms for mapping proteins will provide you with a level of detail you have never before experienced. From our highly accurate free ...
Leading-edge software builds on the patented SILCS technology, using protein-protein interaction and excipient binding predictions to give insights on excipient formulation for biological ...
based inLouvain-la-Neuve, BELGIUM
We are an expert clinical data services and high-level strategic consulting contract research organization (CRO), providing agile clinical trials services for pharmaceutical, biotech, and medical device/diagnostic companies. With a proven track ...
Aiming at optimizing your clinical development strategy, our expert consultants develop the innovative strategies and capabilities needed to launch products with the greatest potential for commercial success and improved patient outcomes. ...
based inMunich, GERMANY
Tubulis generates uniquely matched antibody-drug conjugates (ADCs) through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of protein-drug conjugates by ...
based inCarlsbad, CALIFORNIA (USA)
TargaZyme is a clinical-stage biotechnology company based in San Diego, CA and focused on the research and development of disruptive and novel, off-the-shelf T-Cell products that are aimed at improving the efficacy of T-cell therapies by delivering ...
